Clinical Trial: Safety and Efficacy of Amlotinib in the Treatment of Recurrent Craniopharyngioma

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06970145) titled 'Safety and Efficacy of Amlotinib in the Treatment of Recurrent Craniopharyngioma' on April 22.

Brief Summary: Primary Aim:

To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with amrlotinib .

Secondary Aims:

1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with amrlotinib.

2. To analyze the disease control rate (DCR) of the Anrotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease.

3. Monitor an...